Loading...
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the...
Na minha lista:
| Udgivet i: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
National Academy of Sciences
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5856537/ https://ncbi.nlm.nih.gov/pubmed/29476008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1717820115 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|